よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (36 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
2.
第三版
別冊
引用文献
1.
GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33
bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study
2019. Lancet. 2022 Dec;400(10369):2221-2248.
2.
Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of
Infectious Diseases. 9th ed. Philadelphia: Elsevier 2019.
3.
Pien BC, Sundaram P, Raoof N. et al. The clinical and prognostic importance of positive
blood cultures in adults. Am J Med. 2010 Sep;123(9):819-828.
4.
Thwaites GE, Edgeworth JD, Gkrania-Klotsas E. et al. Clinical management of
Staphylococcus aureus bacteraemia. Lancet Infect Dis 2011 Mar;11(3):208-222.
5.
Bai AD, Morris AM. Management of Staphylococcus aureus bacteremia in adults. CMAJ.
2019 Sep;191(135):E967.
6.
Bai AD, Agarwal A, Steinberg M. et al. Clinical predictors and clinical prediction rules to
estimate initial patient risk for infective endocarditis in Staphylococcus aureus bacteraemia: a
systematic review and meta-analysis. Clin Microbiol Infect. 2017 Dec;23(12):900-906.
7.
Government of South Australia. Staphylococcus aureus Bacteraemia Management Clinical
Guideline. Version 2.0. 2023.
8.
Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected
bacteremia require blood cultures? JAMA 2012;308:502-511.
9.
Lam JC, Stokes W. The Golden Grapes of Wrath - Staphylococcus aureus Bacteremia: A
Clinical Review. Am J Med. 2023 Jan;136(1):19-26.
10. Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS, 2nd. Comparison of
cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillinsusceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014 Sep;58(9):51175124.
11. 抗菌薬 TDM 臨床実践ガイドライン 公益社団法人日本化学療法学会/一般社団法人日本 TDM
学会. 2022. at https://www.chemotherapy.or.jp/uploads/files/guideline/tdm2022.pdf.)
12. Liu C, Bayer A, Cosgrove SE. et al. Clinical practice guidelines by the infectious diseases
society of america for the treatment of methicillin-resistant Staphylococcus aureus infections
in adults and children. Clin Infect Dis 2011 Feb;52(3):e18-55.
13. Figueroa DA, Mangini E, Amodio-Groton M. et al. Safety of high-dose intravenous
daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis
2009 Jul;49(2):177-180.
14. 厚生労働省 バンコマイシン耐性腸球菌感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-14-01.html.)
15. 国立感染症研究所 発生動向調査年別一覧（全数把握）. at
https://www.niid.go.jp/niid/ja/ydata/11530-report-ja2021-30.html.)
16. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev
2000;13:686-707.
36
2.
第三版
別冊
引用文献
1.
GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33
bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study
2019. Lancet. 2022 Dec;400(10369):2221-2248.
2.
Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of
Infectious Diseases. 9th ed. Philadelphia: Elsevier 2019.
3.
Pien BC, Sundaram P, Raoof N. et al. The clinical and prognostic importance of positive
blood cultures in adults. Am J Med. 2010 Sep;123(9):819-828.
4.
Thwaites GE, Edgeworth JD, Gkrania-Klotsas E. et al. Clinical management of
Staphylococcus aureus bacteraemia. Lancet Infect Dis 2011 Mar;11(3):208-222.
5.
Bai AD, Morris AM. Management of Staphylococcus aureus bacteremia in adults. CMAJ.
2019 Sep;191(135):E967.
6.
Bai AD, Agarwal A, Steinberg M. et al. Clinical predictors and clinical prediction rules to
estimate initial patient risk for infective endocarditis in Staphylococcus aureus bacteraemia: a
systematic review and meta-analysis. Clin Microbiol Infect. 2017 Dec;23(12):900-906.
7.
Government of South Australia. Staphylococcus aureus Bacteraemia Management Clinical
Guideline. Version 2.0. 2023.
8.
Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected
bacteremia require blood cultures? JAMA 2012;308:502-511.
9.
Lam JC, Stokes W. The Golden Grapes of Wrath - Staphylococcus aureus Bacteremia: A
Clinical Review. Am J Med. 2023 Jan;136(1):19-26.
10. Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS, 2nd. Comparison of
cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillinsusceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014 Sep;58(9):51175124.
11. 抗菌薬 TDM 臨床実践ガイドライン 公益社団法人日本化学療法学会/一般社団法人日本 TDM
学会. 2022. at https://www.chemotherapy.or.jp/uploads/files/guideline/tdm2022.pdf.)
12. Liu C, Bayer A, Cosgrove SE. et al. Clinical practice guidelines by the infectious diseases
society of america for the treatment of methicillin-resistant Staphylococcus aureus infections
in adults and children. Clin Infect Dis 2011 Feb;52(3):e18-55.
13. Figueroa DA, Mangini E, Amodio-Groton M. et al. Safety of high-dose intravenous
daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis
2009 Jul;49(2):177-180.
14. 厚生労働省 バンコマイシン耐性腸球菌感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-14-01.html.)
15. 国立感染症研究所 発生動向調査年別一覧（全数把握）. at
https://www.niid.go.jp/niid/ja/ydata/11530-report-ja2021-30.html.)
16. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev
2000;13:686-707.
36